Acute lymphocytic leukaemia (ALL) is a cancer of the blood and bone marrow, specifically affecting lymphocytes. The disease progresses rapidly and creates immature blood cells, rather than mature ...

Researchers in South Korea have proposed a novel cancer immunotherapy approach ... in the journal Biomarker Research. B-cell acute lymphoblastic leukemia (B-ALL) is a life-threatening and highly ...

This study is looking at blinatumomab for people with acute myeloid leukaemia (AML). This trial is for adults with B-cell acute lymphoblastic leukaemia that has come back or got worse (relapsed) or ...

Sales of Amgen's Blincyto have grown slowly since it was first introduced a decade ago, but have started to gather momentum thanks to expanded use in acute lymphoblastic leukaemia (ALL), which ...

A study has demonstrated the potential of a novel ligand-based CAR T-cell therapy for targeting CD7-positive T-cell malignancies, including T-cell acute lymphoblastic leukemia (T-ALL) and T-cell ...

Autolus has picked up its first product approval, getting an FDA green light for Aucatzyl as a treatment for patients with aggressive blood cancer acute lymphoblastic leukaemia (ALL). The US ...

He is involved in clinical research using novel therapeutic agents for lymphoma and chronic lymphocytic leukemia, or CLL, as well as immunotherapy (specifically CAR T cell therapy) for lymphoid ...

Swedish cancer patients treated with CAR T-cell therapy show better survival rates and fewer side effects than seen in ...

as a potent selective target for treating acute myeloid leukemia (AML) as well as solid tumors. “Finding cell-surface targets that are specific to malignancies but spared on healthy tissue ...